Tularik Inc. (TLRK) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (481)	6/26/2003 9:10:51 AM
From: mopgcw	of 598

Tularik Expects to Sell Liver-Cancer Drug in 2007, Goeddel Says June 10 (Bloomberg) -- Tularik Inc. aims to start selling its liver-cancer drug T67 in 2007 and reach profitability in 2008, pending the experimental product's late-stage clinical test results, Chief Executive Officer David Goeddel said. The Food & Drug Administration's new fast-track program for cancer drugs could speed up approval of T67, to treat patients with a type of cancer called hepatocellular carcinoma. ``This streamlined process potentially could be advantageous,'' Goeddel said in a televised interview with Bloomberg News. ``We have a drug for which there is no approved chemotherapy, so we find this change at the FDA to be very attractive.'' Amgen Inc. will invest at least $125 million in Tularik for about a 20 percent stake, which will cut Tularik's expenses and aid in research amd development, Goeddel said. South San Francisco, California-based Tularik has four drugs in human clinical trials, including drugs for rheumatoid arthritis and Type 2 diabetes.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next